Insulet added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January.
Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Users can use a dedicated handheld controller or control the system with a secure app on their smartphone, marking another first.
Join us at DeviceTalks Boston on May 10-11, 2022, for a keynote interview with Insulet CEO Shacey Petrovic to learn about the story behind the game-changing Omnipod 5.
We’ve partnered with DeviceTalks to get our readers25% off full conference passes!Use code DTB25 at checkout!
DeviceTalks Boston will unite medtech’s most innovative professionals and help attendees clear troublesome bottlenecks in the critical stages of medical device development. We will explore the trends and technology that are shaping the future of the medical device industry.
